Publications

Publications for John Minna, M.D.

Featured Publications Legend

Featured Publications

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG Cancer 2014 Oct

ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.

Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD Proc. Natl. Acad. Sci. U.S.A. 2014 Sep

Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.

Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach JV, Gold KA, Minna J, Roth JA, Hofstetter WL, Swisher SG, Fang B J. Natl. Cancer Inst. 2014 Sep 106 9

Ras transformation uncouples the kinesin-coordinated cellular nutrient response.

Zaganjor E, Weil LM, Gonzales JX, Minna JD, Cobb MH Proc. Natl. Acad. Sci. U.S.A. 2014 Jul 111 29 10568-73

A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes expanding the repertoire of potential immunotherapeutic targets.

Taguchi A, Taylor AD, Rodriguez J, Celiktas M, Liu H, Ma X, Zhang Q, Wong CH, Chin A, Girard L, Behrens C, Lam WL, Lam S, Minna JD, Wistuba II, Gazdar AF, Hanash SM Cancer Res. 2014 Jun

Loss of miR-125a expression in a model of K-ras-dependent pulmonary premalignancy.

Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner B, Larsen JE, Minna JD, Dubinett SM Cancer Prev Res (Phila) 2014 Jun

Essential role of aldehyde dehydrogenase 1A3 (ALDH1A3) for the maintenance of non-small cell lung cancer stem cells is associated with the STAT3 pathway.

Shao C, Sullivan JP, Girard L, Augustyn A, Yenerall P, Rodriguez J, Liu H, Behrens C, Shay JW, Wistuba II, Minna JD Clin. Cancer Res. 2014 Jun

VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.

Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson M, Simon G, Wang J, Coombes K, Lee JJ, Hong WK, Heymach JV, Minna JD, Wistuba II Clin. Cancer Res. 2014 May

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA JAMA 2014 May 311 19 1998-2006

Aiolos Promotes Anchorage Independence by Silencing p66(Shc) Transcription in Cancer Cells.

Li X, Xu Z, Du W, Zhang Z, Wei Y, Wang H, Zhu Z, Qin L, Wang L, Niu Q, Zhao X, Girard L, Gong Y, Ma Z, Sun B, Yao Z, Minna JD, Terada LS, Liu Z Cancer Cell 2014 May 25 5 575-89

Results 101-110 of 187